Cor­ner Ther­a­peu­tics to hy­per­ac­ti­vate ‘the brains of the im­mune sys­tem’ with $54M launch

Cor­ner Ther­a­peu­tics’ $54 mil­lion Se­ries A will be used to bring new im­munother­a­pies for can­cer and in­fec­tious dis­eases in­to the clin­ic, the com­pa­ny said Thurs­day.

The start­up is led by Steve Altschuler, who co-found­ed Spark Ther­a­peu­tics and was pre­vi­ous­ly CEO of the Chil­dren’s Hos­pi­tal of Philadel­phia. Altschuler serves as the man­ag­ing di­rec­tor of health­care ven­tures at Ziff Cap­i­tal Part­ners, which led Cor­ner’s Se­ries A raise. Cock­rell In­ter­ests, Ta­nis Ven­tures and San­dia Hold­ings al­so con­tributed to the raise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER